Name: CJC-1295 / Ipamorelin (No DAC)
Brand: Amino Club
SKU: prod_01KE40M7AZC0DGNKKTKS18VZJ7
Availability: InStock

CJC-1295 / Ipamorelin (No DAC) | 99%+ Pure Peptide | Amino Club | Amino Club

Frequently Asked Questions

Common questions about CJC-1295/Ipamorelin research

CJC-1295 'with DAC' (Drug Affinity Complex) has a half-life of 5.8-8.1 days due to albumin binding, providing sustained GH elevation. CJC-1295 'without DAC' (also called Mod GRF 1-29) has a half-life of only 30 minutes to 2 hours, allowing for pulsatile GH release that more closely mimics natural physiology. The No DAC version is generally preferred because it preserves the body's natural GH secretion pattern and allows for multiple daily doses without receptor desensitization.

CJC-1295 and Ipamorelin work through complementary pathways. CJC-1295 is a GHRH analog that stimulates the GHRH receptor on pituitary somatotrophs, while Ipamorelin is a ghrelin receptor agonist that amplifies GH release through the GHSR-1a receptor. Research shows that combining GHRH and GHRP peptides produces synergistic effects — approximately 2.7 times greater GH release than either pathway alone, with 43% faster time to peak levels.

Ipamorelin is the first truly selective growth hormone secretagogue. Unlike GHRP-2, GHRP-6, and hexarelin, Ipamorelin releases GH without significantly elevating cortisol, ACTH, prolactin, or aldosterone at GH-releasing doses. This selectivity means fewer side effects — no increased appetite (unlike GHRP-6), no stress hormone elevation (unlike GHRP-2), and no water retention. This makes it the preferred GHRP component for combination therapy.

Research protocols typically recommend administration on an empty stomach (at least 2 hours after eating) to maximize GH release. The most common timing is before bed to amplify the natural nocturnal GH surge that occurs during deep sleep. Some protocols use 2-3 doses per day (morning, post-workout, and bedtime) for enhanced effects. Food, especially carbohydrates and fats, can blunt the GH response.

In Phase II trials, CJC-1295 produced dose-dependent GH increases of 2-10 fold and sustained IGF-1 elevation of 1.5-3 fold lasting 9-11 days after a single injection in healthy adults. Doses of 30-60 mcg/kg were safe and well-tolerated with no serious adverse events. Ipamorelin trials confirmed its selective GH-releasing action without cortisol, prolactin, or aldosterone elevation at therapeutic doses.

CJC-1295/Ipamorelin stimulates your own pituitary to release GH, maintaining natural pulsatile patterns and feedback mechanisms. Synthetic HGH provides a constant exogenous dose that can suppress natural production. Secretagogues generally have a better safety profile, lower cost, and preserve physiologic regulation. However, they require a functioning pituitary gland and may produce less dramatic effects than supraphysiologic HGH doses.

GH secretagogues may interact with glucose metabolism, potentially affecting blood sugar control in diabetics. They should be used cautiously with insulin or oral hypoglycemic agents. Glucocorticoids (like prednisone) can blunt GH release. Somatostatin analogs (like octreotide) will antagonize the effects. There are no known dangerous interactions, but concurrent use with any GH-affecting medication should be discussed with a healthcare provider.

CJC-1295 / Ipamorelin (No DAC)

Two Receptors, One Goal

GHRH Receptor Pathway

Ghrelin/GHS Receptor Pathway

IGF-1 Axis

Why the Combination Works

Why Ipamorelin Stands Out

Growth Hormone Release by Pathway

Key Research Outcomes

CJC-1295 Effects on GH/IGF-1 Axis

Lean Mass & Fat Reduction

Tissue Repair & Healing

Deep Sleep Enhancement

Age-Related GH Decline

Standard Combination Protocol

Clinical Trial Protocol (CJC-1295)

Pharmacokinetic Profile

⚠️Important Notes

Injection site reactions

Flushing/warmth

Headache

Dizziness

Nausea

Ipamorelin Selectivity Advantage

Tolerability Summary

Contraindications for Research Use

💡Researcher Notes

GHRH Analog Component

Selective GHRP Component

Why This Combination

What is the difference between CJC-1295 with DAC and without DAC?

Why combine CJC-1295 with Ipamorelin?

What makes Ipamorelin different from other GHRPs?

When should CJC-1295/Ipamorelin be administered?

What results were seen in clinical trials?

How does this compare to synthetic HGH?

Are there any drug interactions to be aware of?

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

Ipamorelin, the first selective growth hormone secretagogue

On the actions of the growth hormone-releasing hexapeptide, GHRP

A Review of Growth Hormone Secretagogues

Effects of Growth Hormone and Its Secretagogues on Bone

Once-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone (GHRH) Analog, Normalizes Growth in the GHRH Knockout Mouse

⚠️Important Research Notice

All the research peptides you need, with the peace of mind and research community at your fingertips.

Stay Updated with Amino Club

Important Notes

Researcher Notes